| Description | JNJ 303 is a potent blocker of IKs (IC50 : 64 nM). |
| In vitro | Optical mapping was used to measure action potential durations (APDs) in the presence of the IKs blocker JNJ-303 and the IKr blocker E-4031.?JNJ-303 alone did not increase APD.?However, under isoprenaline (ISO), both the application of JNJ-303 and additional E-4031 significantly increased APD.?With JNJ-303, ISO decreased APD significantly more in the epicardium as compared to the endocardium, with subsequent application E-4031 increasing mid- and endocardial APD80 more significantly than in the epicardium.?We found that β-AR stimulation significantly augmented the effect of IKs blocker JNJ-303, in contrast to the reduced effect of IKr blocker E-4031[1]. |
| Target activity | IKs:64 nM |
| molecular weight | 440.98 |
| Molecular formula | C21H29ClN2O4S |
| CAS | 878489-28-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 11 mg/mL (24.94 mM) |
| References | 1. Kang C , Badiceanu A , Brennan J A , et al. β-adrenergic stimulation augments transmural dispersion of repolarization via modulation of delayed rectifier currents IKs and IKr in the human ventricle[J]. Scientific Reports, 2017, 7(1):15922. 2. Emily R Pfeiffer-Kaushik , Godfrey L Smith , Beibei Cai, et al.Electrophysiological Characterization of Drug Response in hSC-derived Cardiomyocytes Using Voltage-Sensitive Optical Platforms.J Pharmacol Toxicol Methods, 99, 106612 Sep-Oct 2019 |